Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
$101.03
-$1.54(-1.52%)
At close: 4:00 PM EST
$101.03
-$1.54(-1.52%)
Day’s Range― - ―
52-Week Range$73.31 - $105.84
Previous CloseN/A
Volume3.30M
Average Volume (3M)13.04M
Market Cap
$252.74B
Enterprise Value$232.84B
Total Cash (Recent Filing)$18.21B
Total Debt (Recent Filing)$41.37B
Price to Earnings (P/E)13.5
Beta0.52
Next Earnings
Feb 03, 2026EPS Estimate
2.05Last Dividend Ex-Date
Sep 15, 2025Dividend Yield3.41%
Share Statistics
EPS (TTM)2.58
Shares Outstanding2,482,022,500
10 Day Avg. Volume16,220,317
30 Day Avg. Volume13,044,815
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda8.45
Forecast
1Y Price Target
$107.23Price Target Upside6.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Cidara is viewed as encouraging and consistent with the company’s prior commentary.
Financial PerformanceMerck reported earnings with a slight beat on the topline and a larger beat on EPS.
Product EfficacyMerck's doravirine/islatravir (DOR/ISL) is just as effective at suppressing HIV replication compared to Gilead's regimen.
Bears Say
Pipeline ChallengesMerck's pipeline pieces like Ohtuvayre and sac-TMT are not yet significant enough to fully alleviate concerns of a revenue decline due to Keytruda LOE.
Product Growth ConcernsUncertainty around Merck's Gardasil franchise and lack of clarity around growth beyond the Keytruda LOE will continue to pressure shares.
Revenue GuidanceGuidance for FY25 revenue was narrowed and slightly revised down.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $105.84 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $252.74B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 03, 2026 which is in 61 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 30, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.362 by $0.218.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.41%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.05.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,482,022,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.58 in its last earnings report, beating expectations of $2.362. Following the earnings report the stock price went down -0.347%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$107.23 (6.14% Upside)
$107.23 (6.14% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 736.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.89%
12-Months-Change
Fundamentals
Return on Equity
39.51%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Merck & Company
Merck & Company, commonly known as Merck, is a leading global healthcare company that specializes in pharmaceuticals, vaccines, biologics, and animal health products. Founded in 1891, Merck operates across various sectors, focusing on innovative therapeutic solutions in areas such as oncology, infectious diseases, cardiovascular diseases, and diabetes. The company is known for its extensive portfolio of prescription medications and vaccines, including the well-known HPV vaccine Gardasil and the diabetes drug Januvia.
MRK Company Deck
MRK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.View all MRK earnings summariesMRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$107.23
▲(6.14% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.05% Mutual Funds
6.37% Other Institutional Investors
46.95% Public Companies and Individual Investors